USPTO issues Notice of Allowance to Emboline's aortic devices for TAVR procedures

Emboline, Inc., an emerging medical device company, has received Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its aortic embolic protection devices for percutaneous heart valve repair and replacement. The Company is initially focused on developing its novel Emboline CAP™ device: a game-changing, next-generation system intended to provide complete protection of the arterial bed (both the cerebrals and the aortic lumen) utilizing a uniquely ported design that maintains tool access through the filter. In addition, Emboline is also developing Emboliner™, a simple-to-use system for protection of the cerebral vessels alone.

Emboline's technologies are derived from intellectual property invented by Amir Belson, M.D., founder of Neoguide Systems, a company that developed platform technology for minimally invasive surgical procedures and was acquired by Intuitive Surgical in 2009.

"Our emergence is timely, given the significant attention on transcatheter aortic valve replacement at this month's TCT 2011 conference," said Scott Russell, Emboline's General Manager. "For these exciting new TAVR procedures to realize their clinical potential, the risk of stroke must be rigorously managed. Our technology is designed not only to eliminate the risk of embolic stroke from TAVR procedures, but it is also the only technology designed to simultaneously shield the aortic lumen in order to protect the rest of the arterial bed as well. No doubt, allowance of this patent fortifies the competitive advantage of our IP portfolio and is a critically important milestone in our comprehensive strategy for device development in the aortic embolic-protection space."